Codexis Announces New Employment Inducement Grants
10 June 2023 - 6:05AM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the approval of equity grants to four new employees
as approved by the Compensation Committee of Codexis’s Board of
Directors. The newly hired employees received equity awards
consisting of an aggregate of (i) options to purchase 41,946 shares
of Codexis common stock and (ii) restricted stock units (RSUs) for
30,201 shares of Codexis common stock as inducement awards under
the company’s 2022 Employment Inducement Award Plan. The grants
were made in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price equal to the closing
price per share of Codexis’ common stock as reported by Nasdaq on
the grant date, and vest over four years, with 25 percent of the
shares vesting on the first anniversary of the grant date, and the
remainder vesting ratably at the end of each subsequent month
thereafter, subject to each employee’s continued service with
Codexis through the applicable vesting dates. The RSUs will entitle
each employee to receive one share of Codexis’ common stock for
each RSU that vests. The RSUs will vest in equal annual
installments on each anniversary of the grant date, until the third
anniversary of such date, subject to each employee’s continued
service with Codexis through the applicable vesting dates.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® technology platform to discover, develop
and enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing,
nucleic acid synthesis and genomic sequencing, and – as
biotherapeutic candidates – they have the potential to treat
challenging diseases. Codexis’ unique enzymes can drive
improvements such as higher yields, reduced energy usage and waste
generation, improved efficiency in manufacturing, greater
sensitivity in genomic and diagnostic applications and potentially
more efficacious therapeutics. For more information,
visit www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024